Ad from GoBoldly PhRMA Ad Campaign - 2017

"The UCLA Brain Tumor Program continues to shine as a beacon of hope, carrying a record of patients with brain tumors living longer than patients treated at any other hospital. Our personalized brain cancer vaccine, DCVax, is the first of its kind and is currently in Phase III clinical trials in 46 centers throughout America. It is on the road to FDA approval as well as clinical trials throughout Europe. Using this vaccine, we are harnessing the patient's immune system, genetics, pathology, brain mapping and a wide database of bioinformatics to optimize outcomes."- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA

Corporate Profile

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.

Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.

Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.

They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.